Skip to main content
. Author manuscript; available in PMC: 2016 Jul 21.
Published in final edited form as: Gene Ther. 2012 Jun 21;20(4):361–369. doi: 10.1038/gt.2012.43

Table 1.

Characteristics and Treatment Regimen of the 14 Subjects who Received Alipogene Tiparvovec

Subject ID Genotype Gender Age Cohort Dose alipogene tiparvovec [gc/kg] Immuno-suppressant regimen
01 P207L/P207L F 60 2 3 × 1011 CsA + MMF
04 P207L/P207L M 50 1 3 × 1011 none
06 P207L/P207L M 51 1 3 × 1011 none
07 P207L/P207L F 56 2 3 × 1011 CsA + MMF
08 P207L/P207L M 28 3 1 × 1012 CsA + MMF
09 P207L/G188E F 62 3 1 × 1012 CsA + MMF
10 P207L/D9N M 42 2 3 × 1011 CsA + MMF
11 P207L/P207L F 48 3 1 × 1012 CsA + MMF
13 P207L/G188E F 40 3 1 × 1012 CsA + MMF
14 P207L/P207L F 51 2 3 × 1011 CsA + MMF
15 P207L/P207L F 50 3 1 × 1012 CsA + MMF
18 P207L/P207L M 37 3 1 × 1012 CsA + MMF
19 P207L/P207L F 28 3 1 × 1012 CsA + MMF
20 P207L/P207L F 36 3 1 × 1012 CsA + MMF

CsA: cyclosporine A (3mg/kg/day)

MMF: mycophenolate mofetil (2g/day)